ADPD Conference 2011, Barcelona, Spain

Get Started. It's Free
or sign up with your email address
Rocket clouds
ADPD Conference 2011, Barcelona, Spain by Mind Map: ADPD Conference 2011, Barcelona, Spain

1. Day 1

1.1. Symposium 7

1.1.1. Symposium 7 Talk 1

1.1.2. Symposium 7 Talk 2 - Professor Fahnestock

1.1.3. Symposium 7 talk 3

1.2. Elan Sponsored Symposium: Hall A

1.2.1. E. Koo talk

1.2.1.1. Literature

1.2.1.1.1. Imbimbo

1.2.1.1.2. Petersen

1.2.1.2. NSAIDS and GMSs

1.2.1.2.1. GSM activity may be one explanation for the apparent protetcive function of NSAIDS in AD

1.2.1.2.2. No definitive in vivo evidence of target engagemetn by GMSs

1.2.1.2.3. Flurizan (R-flurbiprofen) did not adequately test amyloid hypothesis due to lack of activity/brain penetrations

1.2.2. J. McLaurin

1.2.2.1. Fenili et al

1.2.2.1.1. J Mol Med 2007

1.2.2.2. McLaurin et al, Nat Med 12, 801-8-2006

1.2.2.2.1. More papers by author

1.2.2.2.2. Open access papers

1.2.2.3. Chishti 2001

1.2.3. J.O. Rinne

1.2.3.1. Amyloid imaging as a surrogate marker in clinical trials in Alzheimer's Disease

1.2.3.2. Rinne 2010, Lancet Paper

1.2.3.3. Paper on Amyloid PET imaging

1.2.3.4. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. (open access paper)

1.2.3.5. Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer's disease

1.2.3.6. Immunohistochemical visualization of amyloid-beta protein precursor and amyloid-beta in extra- and intracellular compartments in the human brain

1.2.4. M. Buttini

1.2.4.1. What's an ideal animal model for Parkinson's Disease

1.2.4.1.1. Toxin models

1.2.4.1.2. "viral models"

1.2.4.1.3. Mouse models

1.2.4.1.4. Transgenic mice for Afa synuclein

1.3. Symposium 15

1.3.1. M.F. Beal

1.3.2. P. Jenner

1.3.2.1. interpreting the results of the Adagio delayed start study: a mitochondrial mechanism of action for rasagiline

1.3.2.2. ADAGIO study

1.3.2.3. Mitochondrial changes key to pathology of PD

1.3.2.3.1. toxin induced cell death

1.3.2.3.2. familial PD

1.3.2.3.3. sporadic PD

1.3.2.3.4. Preventing mitochondrial abnormalities opens door to neuroprotective strategies

1.3.2.3.5. Rasagiline inhibtis apoptosis via mitochondrial related mechanism

1.3.2.4. Does 1-(R)-aminoindan possess neuroprotective properties against experimental Parkinson's disease?

1.3.3. BJ Bacskai

1.3.3.1. In vivo imaging with multiphoton microscopy

1.3.3.2. Mouse Models of Abeta production

1.3.3.3. APPswe: PS1dE9

1.3.3.4. In vivo imaging of mouse brain

1.3.3.4.1. mice are anesthetized and prepared surgically for imaging.

1.3.3.4.2. The mous is immobilized and placed on the stage of a multiphoton microscope

1.3.3.4.3. 3D imaging of the brain under the windows is performed

1.3.3.5. Individual neurons, neurites and psines can be imaged!

1.3.3.6. Potential model of neurodegeneration model outlined

1.3.4. SM Cardoso

1.3.4.1. Recent work by this author

2. Day 2

2.1. Symposium: management of neurogenic orthostatic hypotension in PD: scientific insights and therapeutic opportunities, Sponsored by Chelsea Therapeutics

2.1.1. P. Le Witt

2.1.1.1. Norepinephrine as a Neurotransmitter

2.1.1.2. Clinical implications of decreased brain norepinephrine

2.1.1.2.1. depression

2.1.1.2.2. cognitive impairment

2.1.1.2.3. etc

2.1.1.3. reference

2.1.1.3.1. Response to 4-month treatment with reboxetine in Parkinson's disease patients with a major depressive episode

2.1.1.3.2. Alpha2-adrenergic agonist clonidine for improving spatial working memory in Parkinson's disease.

2.1.1.3.3. Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease

2.1.2. P. Low

2.1.2.1. Northera (Droxidopa): an orally available norepinephrine replacement therapy for the treatment of symptomatic neurogenic orthostatic hypotension

2.1.2.1.1. not marketed as a drug, investigational, under FDA review (disclaimer)

2.1.2.2. Mechanism of action

2.1.2.3. Clinical trials

2.1.2.3.1. Japan

2.1.2.3.2. Eu

2.1.2.3.3. US

2.1.2.4. Outcome scoring

2.1.2.4.1. orthostatic hypotension scale

2.1.2.5. Patient groups

2.1.2.5.1. Pure autonomic failure

2.1.2.5.2. Multiple System Atrophy

2.1.2.5.3. Parkinson's Disease

2.1.2.6. Chelsea therapeutics

2.1.2.6.1. Safety and efficacy

2.2. Symposium 24: Alpha Synuclein Biology

2.2.1. C. Ballard / Jones

2.2.1.1. Modified Alpha Synuclein in Dementia w Lewy bodies and Parkinson's Dementia

2.2.1.2. Post-translational modifications

2.2.1.2.1. Alter solubility

2.2.1.2.2. phosphorylation, ubiquitination, nitration etc.

2.2.1.2.3. Truncated alpha synuclein

2.2.1.3. Genetics and synucleinopathy

2.2.1.3.1. Parkin

2.2.1.3.2. LRRK2, GBA, DJ-1, PINK1

2.2.1.3.3. PDD and DLB

2.2.1.4. Ubiquitin Proteasome System

2.2.1.4.1. Responsible for degradation and clearance of proteins

2.2.1.4.2. commonly implicated in neurodegenerative diseases

2.2.1.5. Alfa Synuclein detection

2.2.1.5.1. Annika Ohrfelt

2.2.1.6. DYRK1A gene

2.2.1.6.1. Phosphorylation of Alfa Synuclein

2.2.1.6.2. Tau Formation

2.2.1.6.3. Associated with Dementia

2.2.2. M.G. Schlossmacher

2.2.2.1. Sharing some unpublished data

2.2.2.2. His latest papers

2.2.2.2.1. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.

2.2.2.2.2. Translational Research in Neurology and Neuroscience 2011: Movement Disorders

2.2.2.3. GBA-linked PD and Dementia with Lewy body cases are associated with alfa-synuclein-positive pathology

2.2.2.3.1. Does mutant GBA affect alfa-synuclein cells?

2.2.2.3.2. Cullen V, mol Brain 2009

2.2.2.3.3. Cullen, Kahn, Ann Neurol 2011

2.2.2.4. Question: Can the mutant GBA effect on alfa synuclein be reversed by pharmacological treatments of cells?

2.2.2.4.1. Rapamycin

2.2.2.5. GBA proteins promote a rise in exogenous andendogenous alfa syn concentrations in cellular and in vivo models, respectively.

2.2.2.6. References

2.2.2.6.1. Farrer M

2.2.2.6.2. Tomlinson JJ et al 2010

2.2.2.6.3. Aharon-Perets, NEJM 2004

2.2.2.6.4. Lewis A, Mol GEnet Metabol 2004

2.2.2.6.5. Eblan N, NEJM 2005

2.2.2.6.6. Sato C, Mov Disord 2005

2.2.2.6.7. Clark LN, Neurology 2007

2.2.2.6.8. Clark LN Arch. Neurol 2009

2.2.2.6.9. Neumann J et al Brain 2009

2.2.2.6.10. Sidransky E, NEJM 2009

2.2.3. P. Sardi

2.2.3.1. Association between gaucher disease and synucleinopathies

2.2.3.2. no notes made here

2.2.4. K. Vekrellis

2.2.4.1. Alfa-synuclein secretion is partially via exosomes

2.2.4.1.1. in lumen

2.2.4.1.2. in membrane

2.2.4.1.3. is secretion good or bad?

2.2.4.1.4. We have not seen the alfa synuclein been internalised

2.2.4.2. Determination of alfa synuclein concentration using a novel ultra-sensitive ELISA

2.2.4.2.1. 0.01 nanogram/ml sensitivity

2.2.5. T. Bartels

2.2.5.1. Alfa synuclein

2.2.5.1.1. folded

2.2.5.1.2. unfolded

2.2.5.1.3. pathway

2.2.5.1.4. Peter Landsbury model: aggregation cascade leads to PD

2.2.5.1.5. Native PAGE of cell lysates

2.2.5.1.6. STEM

2.2.5.1.7. Sedimentation equilibrium AUC

2.2.5.1.8. Tetrameric alfasynuclein natively folded and does not undergo conformational change upon lipid interaction

2.2.5.1.9. Does folded alfa syn aggregate more than monomer

2.2.5.1.10. Alfa synuclein model same as this one

2.2.5.1.11. Pharmaceutical molecules

2.2.5.2. PhD in biophysics

2.2.6. C. Kim

2.2.6.1. not reported

2.3. Innovative approaches and biomarkers in parkinson's Disease, Session sponsored by Orizon Genomics

2.3.1. K. Beyer

2.3.2. G. Linazasoro

2.3.3. T. Maes

2.3.3.1. Epigenetics and Parkinson's Disease

2.3.3.2. epigenetics important in learning and memory

2.3.3.3. epigenetics

2.3.3.3.1. young field

2.3.3.4. Epigenetics may play a role in sporadic PD

2.3.3.4.1. reduced methylation can occur

2.3.3.4.2. may lead to increased expression of Alfa synuclein

2.3.3.4.3. Changes in telomere length may play a role

2.3.3.4.4. Oryzon company

2.3.3.4.5. Reduction in Gene expression Park 5

2.3.3.4.6. Ubiquitin Carboxyterminal Hydrolase 1

3. Day 3

4. Day 4

5. Pre - Conference

5.1. Memory loss in Alzheimer disease: underlying mechanisms and therapeutic targets, under the auspices of MEMOSAD

5.1.1. #ADPD Tau, ABeta proteins and neurodegeneration (blog post)

5.2. Opening Ceremony

5.2.1. http://www.youtube.com/watch?v=Fp0nXEoZWDk&feature=channel_video_title

6. Author of notes

6.1. Paul de Roos

6.2. http://www.twitter.com/paulderoos

6.2.1. Live Conference updates

6.2.2. Conversation thread: #ADPD